2-SGLT2 Inhibition: A New Agent in Armamentarium of Obesity and Diabetes


Dr Beena Bansal, New Delhi    13 January 2018

  1. Two members of the studied class show overall CV benefit. They also suggest the possibility of dramatic kidney protection in DM2.
  2. Future studies will test these hypotheses formally in dedicated kidney outcome trials and may offer the potential to dramatically reduce the risk of kidney failure in people with diabetes.
  3. They will also provide important additional information regarding the safety and efficacy of SGLT2i in people with established CKD, and in people with nondiabetic kidney disease.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.